{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:22:41Z","timestamp":1782706961058,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":68,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.prdoa.2025.100317","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T18:42:38Z","timestamp":1742150558000},"page":"100317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Impact of pimavanserin on prescribing practices in parkinson disease"],"prefix":"10.1016","volume":"12","author":[{"given":"Thanh Phuong","family":"Pham Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vy","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.prdoa.2025.100317_b0005","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s13311-020-00875-w","article-title":"Management of psychiatric disorders in Parkinson's disease: Neurotherapeutics - Movement Disorders Therapeutics","volume":"17","author":"Weintraub","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1016\/j.prdoa.2025.100317_b0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/1060028017703992","article-title":"Evidence-based review of pharmacotherapy used for Parkinson's disease psychosis","volume":"51","author":"Wilby","year":"2017","journal-title":"Ann. Pharmacother."},{"issue":"9916","key":"10.1016\/j.prdoa.2025.100317_b0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.prdoa.2025.100317_b0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2020.05.026","article-title":"Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review","volume":"75","author":"Kyle","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"issue":"8","key":"10.1016\/j.prdoa.2025.100317_b0025","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.prdoa.2025.100317_b0030","article-title":"Exploring the kinetic selectivity of antipsychotics for dopamine D<sub>2<\/sub> and 5-HT<sub>2A<\/sub> receptors: implications for the prevalence of EPS and receptor occupancy","author":"Sykes","year":"2021","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.prdoa.2025.100317_b0035","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis","volume":"33","author":"Lako","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.prdoa.2025.100317_b0040","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.prdoa.2025.100317_b0045","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.prdoa.2025.100317_b0050","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","author":"Parkinson Study Group","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.prdoa.2025.100317_b0055","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.prdoa.2025.100317_b0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2025.100317_b0065","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/NDT.S5335","article-title":"A randomized controlled trial of quetiapine for psychosis in Parkinson's disease","volume":"5","author":"Shotbolt","year":"2009","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.prdoa.2025.100317_b0070","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.10374","article-title":"Long-term outcome of quetiapine use for psychosis among Parkinsonian patients","volume":"18","author":"Fernandez","year":"2003","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.prdoa.2025.100317_b0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.prdoa.2025.100317_b0080","doi-asserted-by":"crossref","unstructured":"By the American Geriatrics Society Beers Criteria Update Expert Panel, American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults, J Am Geriatr Soc 71(7) (2023) 2052-2081.","DOI":"10.1111\/jgs.18372"},{"key":"10.1016\/j.prdoa.2025.100317_b0085","unstructured":"National Institute for Health and Care Excellence, Parkinson\u2019s disease in adults, 2017. https:\/\/www.nice.org.uk\/guidance\/ng71\/resources\/parkinsons-disease-in-adults-pdf-1837629189061. (Accessed February 11 2025)."},{"issue":"7","key":"10.1016\/j.prdoa.2025.100317_b0090","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00228-015-1860-9","article-title":"The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries","volume":"71","author":"Renom-Guiteras","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.prdoa.2025.100317_b0095","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s41999-023-00777-y","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 3","volume":"14","author":"O'Mahony","year":"2023","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.prdoa.2025.100317_b0100","doi-asserted-by":"crossref","DOI":"10.1007\/s40801-024-00433-2","article-title":"Falls and fractures among nursing home residents treated with pimavanserin versus other atypical antipsychotics: analysis of medicare beneficiaries with Parkinson's disease psychosis","author":"Rajagopalan","year":"2024","journal-title":"Drugs Real World Outcomes"},{"issue":"9","key":"10.1016\/j.prdoa.2025.100317_b0105","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1212\/WNL.0000000000201627","article-title":"Costs and Utilization of New-to-Market Neurologic Medications","volume":"100","author":"Reynolds","year":"2023","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.prdoa.2025.100317_b0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1060028017693029","article-title":"Pimavanserin: A novel antipsychotic for Parkinson's disease psychosis","volume":"51","author":"Bozymski","year":"2017","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.prdoa.2025.100317_b0115","first-page":"368","article-title":"Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated With Parkinson's Disease","volume":"42","author":"Cruz","year":"2017","journal-title":"P T"},{"issue":"3","key":"10.1016\/j.prdoa.2025.100317_b0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jagp.2021.07.018","article-title":"Medicare claims data underestimate hallucinations in older adults with dementia","volume":"30","author":"Hamedani","year":"2022","journal-title":"Am. J. Geriatr. Psychiatry"}],"container-title":["Clinical Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112525000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112525000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:20:38Z","timestamp":1775820038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112525000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":24,"alternative-id":["S2590112525000210"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2025.100317","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of pimavanserin on prescribing practices in parkinson disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2025.100317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100317"}}